single-chain antibody

single-chain antibody

A synthetic antibody based on a single-chain fragment, which is a fusion protein of the variable regions of the heavy and light chains of immunoglobulins, connected with a short linker peptide of 10–25 amino acids. Single chains are one of the smallest possible formats for recombinant antibodies, and have potential roles as diagnostic tools and therapeutic agents.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
According to the company, Brolucizumab (RTH258) is a humanized single-chain antibody fragment (scFv) to reach this stage of development.
Song et al., "SPECT and fluorescence imaging of vulnerable atherosclerotic plaque with a vascular cell adhesion molecule 1 single-chain antibody fragment," Atherosclerosis, vol.
Dubel, "A helper phage to improve single-chain antibody presentation in phage display," Nature Biotechnology, vol.
COPENHAGEN -- An ultrasmall yet highly potent single-chain antibody fragment directed against tumor necrosis factor-alpha showed promise for the treatment of Behcet's disease flares in a pilot phase II study.
Bypassing hybridoma technology: HLA-C reactive human single-chain antibody fragments (scFv) derived from a synthetic phage display library (HuCAL) and their potential to discriminate HLA class 1 specificities.
ESBA105 is a single-chain antibody fragment directed against TNF?.
Use of an in vivo biotinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies.
This mechanism of action has been validated by experiments with single-chain antibody fragments containing the antibody binding site (15).
and Inhale announced a broad strategic alliance that includes a collaboration to develop three products using Inhale's Inhance(TM) pulmonary delivery platform or SEDS(TM) supercritical fluids platform; an agreement making Inhale solely responsible for licensing Enzon's PEG patents, which includes over 40 US patents; an option for Enzon to license Inhale's PEGylation patents; and an agreement to explore the development of non-invasive delivery of single-chain antibody products via the pulmonary route.
According to researcher Robert Bird of the Gaithersburg, Md.-based company, recent tests show this "single-chain antibody" binds specifically to its antigen.
According to the company, LME 636 is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery.
During the last decade combinatorial technologies have enabled the selection of a variety of monoclonal single-chain antibody fragments (scFv) against all types of antigens and epitopes (8-10).
Full browser ?